4 May 2009: NorDiag has appointed Atlantic Biologicals Diagnostics L.L.C. as non-exclusive distributor for a selection of its infectious disease products for USA.

Atlantic Biologicals  is a comprehensive provider of healthcare solutions. The company is a premier distributor of brand, generic and critical care pharmaceuticals as well as diagnostic products. They service hospitals, physicians' offices, oncology clinics, diagnostic centers, freestanding clinics and home infusion facilities. The corporate headquarters are strategically located in South Florida. Additional distribution centers are located throughout the country.

Nancy Murphy, President of NorDiag Inc said, "We are excited about the opportunity to work with the newly formed Atlantic Biologicals Diagnostics, which is a sister company of Atlantic Biologicals. This will expand the NorDiag's commercial potential in the United States."

Mårten Wigstøl CEO of NorDiag ASA says, "This is part of our strategy to increase geographical coverage and increase distribution power. We are excited that Atlantic Biologicals shows trust in our products by incorporating them into their product portfolio. The US.market is a key to success for diagnostic companies.  We have therefore recently elected a new chairman of the board located in USA, who will also be active in building the marketing structure for NorDiags product portfolio."

"The NorDiag brand represents an important addition to our diagnostics expansion"; and, Karen L. Moody, President, Atlantic Biologicals Diagnostics L.L.C, added "we are delighted in our new partnership with a technology leader such as NorDiag."

NorDiag has through its wholly owned subsidiary NorDiag Inc. started to penetrate the US market with its instruments and reagents. NorDiag has already established a solid foothold and market share in Scandinavia and the strategy is to use the Scandinavian market as a reference market for further commercialization and geographic expansion. Atlantic Biologicals Diagnostics L.L.C. is expected to give a major contribution to this process, with their network, competence and industry knowledge.

Contact:
CEO Mårten Wigstøl, phone +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for use in diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis, MRSA and DNA from stool. Applications for respiratory pathogens and viruses are under development. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the notice in Norwegian here